Impact of surgical resection rate on survival in gastric cancer: nationwide study.

BACKGROUND: There are marked geographical variations in the proportion of patients undergoing resection for gastric cancer. This study investigated the impact of resection rate on survival. METHODS: All patients with potentially curable gastric cancer between 2006 and 2017 were identified from the Swedish National Register of Oesophageal and Gastric Cancer. The annual resection rate was calculated for each county per year. Resection rates in all counties for all years were grouped into tertiles and classified as low, intermediate or high. Survival was analysed using the Cox proportional hazards model. RESULTS: A total of 3465 patients were diagnosed with potentially curable gastric cancer, and 1934 (55.8 per cent) were resected. Resection rates in the low (1261 patients), intermediate (1141) and high (1063) tertiles were 0-50.0, 50.1-62.5 and 62.6-100 per cent respectively. The multivariable Cox analysis revealed better survival for patients diagnosed in counties during years with an intermediate versus low resection rate (hazard ratio (HR) 0.81, 95 per cent c.i. 0.74 to 0.90; P < 0.001) and high versus low resection rate (HR 0.80, 0.73 to 0.88; P < 0.001). CONCLUSION: This national register study showed large regional variation in resection rates for gastric cancer. A higher resection rate appeared to be beneficial with regard to overall survival for the entire population.

Geographical differences in cancer treatment and survival for patients with oesophageal and gastro-oesophageal junctional cancers.

BACKGROUND: Only around one-quarter of patients with cancer of the oesophagus and the gastro-oesophageal junction (GOJ) undergo surgical resection. This population-based study investigated the rates of treatment with curative intent and resection, and their association with survival. METHODS: Patients diagnosed with oesophageal and GOJ cancer between 2006 and 2015 in Sweden were identified from the National Register for Oesophageal and Gastric Cancer (NREV). The NREV was cross-linked with several national registries to obtain information on additional exposures. The annual proportion of patients undergoing treatment with curative intent and surgical resection in each county was calculated, and the counties divided into groups with low, intermediate and high rates. Treatment with curative intent was defined as definitive chemoradiation therapy or surgery, with or without neoadjuvant oncological treatment. Overall survival was analysed using a multilevel model based on county of residence at the time of diagnosis. RESULTS: Some 5959 patients were included, of whom 1503 (25·2 per cent) underwent surgery. Median overall survival after diagnosis was 7·7, 8·8 and 11·1 months respectively in counties with low, intermediate and high rates of treatment with curative intent. Corresponding survival times for the surgical resection groups were 7·4, 9·3 and 11·0 months. In the multivariable analysis, a higher rate of treatment with curative intent (time ratio 1·17, 95 per cent c.i. 1·05 to 1·30; P < 0·001) and a higher resection rate (time ratio 1·24, 1·12 to 1·37; P < 0·001) were associated with improved survival after adjustment for relevant confounders. CONCLUSION: Patients diagnosed in counties with higher rates of treatment with curative intent and higher rates of surgery had better survival.

ANTECEDENTES: En los pacientes con cáncer en el esófago y de la unión gastroesofágica (gastroesophageal junction, GOJ), solamente en una cuarta parte se practica una resección quirúrgica. Este estudio de base poblacional analizó las tasas de tratamiento con intención curativa y de resección y su asociación con la supervivencia. MÉTODOS: A partir del Registro Nacional Sueco de Cáncer de Esófago y Estómago (National Register for Oesophageal and Gastric Cancer, NREV), se identificaron los pacientes diagnosticados de cáncer de esófago y de la GOJ entre 2006-2015. El NREV se cruzó con otros registros nacionales para obtener información adicional. Se calculó la proporción anual de pacientes tratados con intención curativa o mediante resección quirúrgica en cada una de las áreas territoriales de los condados y se categorizaron en baja, intermedia y alta. El tratamiento con intención curativa se definió como la quimiorradioterapia definitiva (definitive chemoradiation therapy, dCRT) o la cirugía, con o sin tratamiento oncológico neoadyuvante. Se analizó la supervivencia global con un modelo multinivel basado en el condado de residencia en el momento del diagnóstico. RESULTADOS: Se incluyeron 5.959 pacientes, de los que 1.503 (25,2%) fueron tratados quirúrgicamente. La mediana de supervivencia global después del tratamiento con intención curativa fue de 7,7, 8,8 y 11,1 meses para los condados de volumen bajo, intermedio y alto. Para el grupo de cirugía fue de 7,4, 9,3 y 11,0 meses, respectivamente. En el análisis multivariable, una mayor tasa de tratamiento con intención curativa y una mayor tasa de resección se asociaron con una mejor supervivencia (tiempo ganado 1,17; i.c. del 95% 1,05-1,30, P < 0,001 y tiempo ganado 1,24; i.c. del 95% 1,12-1,37, P < 0,001) después del ajuste para los factores principales de confusión. CONCLUSIÓN: Los pacientes diagnosticados en condados con tasas altas de tratamiento con intención curativa y de cirugía tuvieron una mejor supervivencia.

Nationwide study of the impact of D2 lymphadenectomy on survival after gastric cancer surgery.

BACKGROUND: Gastrectomy including D2 lymphadenectomy is regarded as the standard curative treatment for advanced gastric cancer in Asia. This procedure has also been adopted gradually in the West, despite lack of support from RCTs. This study sought to investigate any advantage for long-term survival following D2 lymphadenectomy in routine gastric cancer surgery in a Western nationwide population-based cohort. METHODS: All patients who had a gastrectomy for cancer in Sweden in 2006-2017 were included in the study. Prospectively determined data items were retrieved from the National Register of Oesophageal and Gastric Cancer. Extent of lymphadenectomy was categorized as D1+/D2 or the less extensive D0/D1 according to the Japanese Gastric Cancer Association classification. Overall survival was analysed and, in addition, a variety of possible confounders were introduced into the Cox proportional hazards regression model. RESULTS: A total of 1677 patients underwent gastrectomy, of whom 471 (28·1 per cent) were classified as having a D1+/D2 and 1206 (71·9 per cent) a D0/D1 procedure. D1+/D2 lymphadenectomy was not associated with higher 30- or 90-day postoperative mortality. Median overall survival for D1+/D2 lymphadenectomy was 41·5 months with a 5-year survival rate of 43·7 per cent, compared with 38·5 months and 38·5 per cent respectively for D0/D1 (P = 0·116). After adjustment for confounders, in multivariable analysis survival was significantly higher after D1+/D2 than following D0/D1 lymphadenectomy (hazard ratio 0·81, 95 per cent c.i. 0·68 to 0·95; P = 0·012). CONCLUSION: This national registry study showed that long-term survival after gastric cancer surgery was improved after gastrectomy involving D1+/D2 lymphadenectomy compared with D0/D1 dissection.

ANTECEDENTES: En Asia, la gastrectomía con linfadenectomía D2 asociada se considera el tratamiento curativo estándar para el cáncer gástrico avanzado. Este procedimiento se ha adoptado gradualmente también en el mundo occidental a pesar de la falta de apoyo de los ensayos clínicos aleatorizados. En este estudio hemos tratado de investigar cualquier ventaja sobre la supervivencia a largo plazo tras la linfadenectomía D2 de rutina en una cohorte de base poblacional de cirugía del cáncer gástrico en un país occidental. MÉTODOS: Se incluyeron todos los pacientes que fueron sometidos a gastrectomía por cáncer en Suecia desde 2006-2017. Se recuperaron datos registrados prospectivamente del Registro Nacional de Cáncer de Esófago y Estómago. La extensión de la linfadenectomía se categorizó en D1+/D2 o cuando fue menos amplia en D0/D1 de acuerdo con la clasificación de la Japanese Gastric Cancer Association. Se analizó la supervivencia global y, además, se introdujeron diversos factores de confusión en un modelo de regresión de riesgos proporcional de Cox. RESULTADOS: Un total de 1.677 pacientes fueron sometidos a gastrectomía, de los cuales 471 (28%) fueron clasificados como D1+/D2 y 1.206 (72%) como D0/D1. La linfadenectomía D1+/D2 no se asoció con una mayor mortalidad postoperatoria a los 30 y 90 días. La mediana de la supervivencia global para la linfadenectomía D1+/D2 fue de 41,5 meses con una tasa de supervivencia a los 5 años de 44% comparado con 38,5 meses y 39%, respectivamente, para D0/D1 (P = 0,116). Después de ajustar por los factores de confusión en el análisis multivariable, la supervivencia fue significativamente más alta en la linfadenectomía D1+/D2 comparada con D0/D1 (cociente de riesgos instantáneos, hazard ratio, HR 0,81 (i.c. del 95% 0,68-0,95), P = 0,012)). CONCLUSIÓN: Este estudio del registro nacional mostró que la supervivencia a largo plazo tras cirugía del cáncer gástrico mejoró después de una gastrectomía que incluya linfadenectomía D1+/D2 en comparación con la disección D0/D1.

Computed tomography and magnetic resonance imaging of diffuse pigmented villonodular synovitis: report of a case.

We describe the computed tomographic (CT) and magnetic resonance imaging (MRI) features of a surgically proven case of diffuse pigmented villonodular synovitis (PVNS) of the knee in a 34-year-old woman. A complex mass consisting of solid and multicystic components was clearly demonstrated by CT and MRI. The solid part showed homogeneous hypodense attenuation relative to adjacent muscles on CT scans, but it showed inhomogeneous signal intensity on spin echo T1- and T2-weighted images (WI). The solid component enhanced homogeneously on CT scans but heterogeneously on MR images. Multiseptated enhancement of the cystic component on both CT and MR images were displayed. All of the above features were better demonstrated on MRI. Multiple marked hypointense round and patchy areas, and also a few areas isointense to subcutaneous fat within the lesion were also found on T1WI, proton density WI and T2WI. These characteristic MRI features of PVNS correlated well with its histologic structures: depositions of hemosiderin and fat in the proliferative synovial villi and bloody cystic content. These features may help to distinguish PVNS from other disease entities arising from the synovium.

Magnetic resonance imaging of acoustic schwannomas.

The magnetic resonance imaging (MRI) findings of 27 histologically proven acoustic schwannomas in 24 patients (13 men, 11 women, age 20-79 yr) are described in detail. Three patients had bilateral tumors. Twenty-two tumors (82%) had intra- and extracanalicular components, three tumors (11%) were limited to the internal auditory canal (IAC) and two tumors (7%) were limited to the cerebellopontine angle (CPA). The diameters of extracanalicular lesions in the CPA ranged from 12 to 50 mm, and most of them were round in shape. All IAC portions of CPA tumors had a funnel-shaped appearance on the axial images and short-club-shaped configuration on the coronal images. There was strong homogeneous contrast enhancement of the solid components in 12 tumors (44%) and heterogeneous enhancement in 15 tumors (56%). The cystic components of the tumors correlated well with the histologic features. All tumors could be demonstrated in their enterity by MRI. The "short-club sign", first described in this study, helped to confirm the intracanalicular component of acoustic schwannomas, which were usually found in the cerebellar cistern. The results of this study show that MRI is a sensitive imaging modality for the assessment of acoustic schwannomas located at the CPA or IAC, or in both regions. MRI is non-invasive and does not involve ionizing radiation. It should be considered the imaging examination of choice to evaluate patients with suspected acoustic schwannomas.

[Computed tomography of gastric carcinoma using water as a contrast agent].

To overcome the problem of poor mixing of gastrointestinal tract contents with a diluted iodinated contrast agent in abdominal computed tomography, pure water was adopted as an oral contrast agent. In 25 cases of clinically suspected gastric carcinoma, a subsequent pathological examination revealed six cases of early gastric cancer and 19 cases of advanced gastric cancer. We performed CT of the stomach using the following revised procedure: patients were given 600-1000 mL of water by mouth after an intramuscular dose of Buscopan to distend and immobilize the stomach. Gastric mucosal enhancement and the poorer enhanced submucosal layer were demonstrated by a bolus intravenous injection of iodine-containing contrast medium using an automatic injector synchronized with the CT machine. Based on abnormal gastric wall thickening and the abnormal mural enhancement patterns, an accuracy of 96% was attained in differentiating early gastric cancer from advanced gastric cancer, but the detection rates for extragastric invasion, gastric ulcers and lymphadenopathy were 67%, 43% and 63%, respectively. CT staging of gastric cancer was 72%, and was especially accurate for stages I and IV. Water as oral contrast agent for CT of the GI tract was readily accepted by patients and caused no side effects. Using water as an oral contrast for gastric CT is of great help in staging gastric cancer.